Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Published:2024-07 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

King Brett,Senna Maryanne M.,Mesinkovska Natasha A.,Lynde Charles,Zirwas Matthew,Maari Catherine,Prajapati Vimal H.,Sapra Sheetal,Brzewski Pawel,Osman Lawrence,Hanna Sameh,Wiseman Marni C.,Hamilton Colleen,Cassella James

Funder

Concert Pharmaceuticals

Sun Pharma

Publisher

Elsevier BV

Reference11 articles.

1. Alopecia areata - current understanding and management;Lintzeri;J Dtsch Dermatol Ges,2022

2. Burden of illness in alopecia creata: a cross-sectional online survey study;Mesinkovska;J Investig Dermatol Symp Proc,2020

3. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity;Muntyanu;J Eur Acad Dermatol Venereol,2023

4. A comprehensive literature review of JAK inhibitors in treatment of alopecia areata;Dillon;Clin Cosmet Investig Dermatol,2021

5. Systemic treatments for alopecia areata: a systematic review;Lai;Australas J Dermatol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP